Capstone Investment Advisors
PCVX icon

Capstone Investment Advisors’s Vaxcyte PCVX Stock Holding History

Capstone Investment Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,195
Closed -$439K – 1938
2025
Q3 		$439K Buy
+12,195
New +$404K ﹤0.01% 1466
2024
Q2 		– Sell
-109,389
Closed -$7.47M – 2366
2024
Q1 		$7.47M Buy
+109,389
New +$7.57M 0.03% 328

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Capstone Investment Advisors's PCVX Position: Q4 2025 in Review

Capstone Investment Advisors sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 12,195 shares — an estimated $439K sold.

Capstone Investment Advisors first reported a position in PCVX in Q1 2024 and held it in 2 quarters. The position peaked at $7.47M in Q1 2024. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

  • Capstone Investment Advisors reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
  • Capstone Investment Advisors sold 12,195 Vaxcyte shares in Q4 2025, an estimated $439K.
  • Capstone Investment Advisors first reported a position in Vaxcyte in Q1 2024 and held it in 2 quarters.
  • Capstone Investment Advisors's Vaxcyte position peaked at $7.47M in Q1 2024.
  • 295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Capstone Investment Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.